Allergan Inc., of Irvine, Calif., said after consultation with its independent financial and legal advisors, its board unanimously determined that the unsolicited exchange offer to acquire all outstanding common shares of Allergan from Valeant Pharmaceuticals International Inc., of Laval, Quebec, is grossly inadequate, substantially undervalues the company, creates significant risks and uncertainties for company stockholders and is not in their best interests.